SP
NBIX icon

Symmetry Partners’s Neurocrine Biosciences NBIX Stock Holding History

Symmetry Partners’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,616
Closed -$222K – 359
2024
Q2 		$222K Sell
1,616
-248
-13% -$34K 0.01% 477
2024
Q1 		$257K Hold
1,864
– – 0.02% 463
2023
Q4 		$246K Buy
+1,864
New +$215K 0.01% 444

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Symmetry Partners's NBIX Position: Q3 2024 in Review

Symmetry Partners sold out of Neurocrine Biosciences (NBIX) in Q3 2024, closing a stake of 1,616 shares — an estimated $222K sold.

Symmetry Partners first reported a position in NBIX in Q4 2023 and held it in 3 quarters. The position peaked at $257K in Q1 2024. 574 funds tracked by Wall St. Rank hold NBIX as of Q3 2024.

  • Symmetry Partners reported no remaining Neurocrine Biosciences position as of Q3 2024 after selling out during the quarter.
  • Symmetry Partners sold 1,616 Neurocrine Biosciences shares in Q3 2024, an estimated $222K.
  • Symmetry Partners first reported a position in Neurocrine Biosciences in Q4 2023 and held it in 3 quarters.
  • Symmetry Partners's Neurocrine Biosciences position peaked at $257K in Q1 2024.
  • 574 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2024.

Based on Symmetry Partners's 13F filing for Q3 2024, filed 29 Oct 2024.